Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials
Australian Prescriber, 45 (2), 3840
While GLP-1 medications may reduce appetite and caloric intake, they can also lead to a reduction in overall protein consumption, which is vital for muscle maintenance and growth
doi: 10.1016/S2213-8587(22)00340-0 [DOI] [PubMed] [Google Scholar] 86.Jakhar K, Vaishnavi S, Kaur P, Singh P, Munshi A
3 s Data are for the full analysis population from the in-trial period (from randomization to the end of trial participation)
The best peptide vendors guide helps identify reputable sources, though no research peptide supplier can match pharmaceutical grade manufacturing standards